UK Biotech Mergers and Acquisitions Activity on the Rise

GSK is in talks to acquire cancer biotech company Nuvalent for more than $9 billion, according to reports on June 9, 2026. This potential acquisition would rank as one of the largest deals for the UK-based drugmaker.

What is the scale of the Nuvalent acquisition?

The discussions involve a valuation exceeding $9 billion for Nuvalent, a firm specializing in cancer biotechnology. If completed, the transaction would be one of the most significant acquisitions in the history of the UK drugmaker.

How does this deal reflect current biotech trends?

The pursuit of Nuvalent comes as merger and acquisition activity within the biotechnology sector has accelerated throughout 2026. The deal aligns with a broader industry trend of larger pharmaceutical companies acquiring specialized biotech firms to expand their therapeutic pipelines.